




CLAIMS

What is claimed is:

1. A small molecule compound that specifically inhibits CDK8 and CDK19 having the structural formula I or II:



wherein each B is independently hydrogen or



provided that at least one B is hydrogen and not more than one B is hydrogen;

D is selected from -NH, -N-lower alkyl, or O;

and n is 0-2.

2. The small molecule compound according to claim 1, wherein lower alkyl is methyl.
3. The small molecule compound according to claim 1, wherein n is 0 or 1.

4. The small molecule compound according to claim 1, selected from the group consisting of SNX2-1-162, SNX2-1-163, SNX2-1-164, SNX2-1-165, SNX2-1-166 and SNX2-1-167.
5. A pharmaceutical formulation comprising the compound according to any of claims 1 to 4 and a physiologically acceptable carrier or diluent.
6. Use of a therapeutically effective amount of a pharmaceutical formulation according to claim 5 in the manufacture of a medicament for treating a mammal having a CDKI-mediated disease.
7. The use according to claim 6, wherein the CDKI-mediated disease is selected from the group consisting of Alzheimer's disease, other dementias, amyloidosis, atherosclerosis, renal disease, viral diseases, cancer and HIV infection.
8. Use of a small molecule compound according to any of claims 1 to 4 in the manufacture of a medicament for treating a tumor that expresses β -catenin in a patient.
9. A small molecule compound that specifically inhibits CDK8/19 according to any of claims 1 to 4 for use in chemoprotecting a patient at risk for developing cancer.
10. A small molecule compound according to any of claims 1 to 4 that specifically inhibits CDK8/19 following debulking for use in preventing cancer recurrence or metastasis in a patient who has undergone debulking treatment for a tumor.
11. The small molecule compound according to claim 10, wherein the cancer is an ovarian or breast cancer.
12. A small molecule compound that specifically inhibits CDK8/19 according to any of claims 1 to 4 for use in preventing tumor invasion in a patient.
13. Use of a small molecule compound according to any of claims 1 to 4 that specifically inhibits CDK8/19 in combination with a DNA damaging agent in the manufacture of a medicament for treating cancer in a patient.

14. The use according to claim 13, wherein the cancer is an ovarian or breast cancer.

15. A small molecule compound that specifically inhibits CDK8/19 according to any of claims 1 to 4 for use in inhibiting tumor-promoting factor secretion by one or more of fibroblasts and stromal cells in a patient, wherein the secretion is induced by a DNA-damaging agent.

16. A small molecule compound according to any of claims 1 to 4 that specifically inhibits CDK8/19 in combination with an adjuvant therapy for use in improving the efficacy of adjuvant therapy given to a patient in combination with surgery.

17. Use of a small molecule compound that specifically inhibits CDK8/19 according to any of claims 1 to 4 in the manufacture of a medicament for treating breast cancer in a patient.

18. The small molecule compound that specifically inhibits CDK8/19 according to any of claims 9 to 12 and 15 to 16, wherein the small molecule compound is administered orally.

19. A small molecule compound that specifically inhibits CDK8/19 wherein the small molecule compound is selected from the group consisting of SNX2-1-150, SNX2-1-151, SNX2-1-152, SNX2-1-153, SNX2-1-154, SNX2-1-155, SNX2-1-157 and SNX2-1-158.